MX2016007407A - Peptidos resistentes a proteasa. - Google Patents
Peptidos resistentes a proteasa.Info
- Publication number
- MX2016007407A MX2016007407A MX2016007407A MX2016007407A MX2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- methyl
- protease
- alpha
- resistant peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108091005804 Peptidases Proteins 0.000 title abstract 4
- 239000004365 Protease Substances 0.000 title abstract 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108010088406 Glucagon-Like Peptides Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- HYOWVAAEQCNGLE-JTQLQIEISA-N alpha-methyl-L-phenylalanine Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-JTQLQIEISA-N 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000010647 peptide synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915662P | 2013-12-13 | 2013-12-13 | |
| PCT/EP2014/077240 WO2015086686A2 (en) | 2013-12-13 | 2014-12-10 | Protease resistant peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007407A true MX2016007407A (es) | 2016-12-12 |
Family
ID=52021207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007407A MX2016007407A (es) | 2013-12-13 | 2014-12-10 | Peptidos resistentes a proteasa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160318987A1 (enExample) |
| EP (2) | EP3080153A2 (enExample) |
| JP (1) | JP2017502003A (enExample) |
| KR (1) | KR20160098406A (enExample) |
| CN (1) | CN105849123A (enExample) |
| AU (1) | AU2014363547A1 (enExample) |
| BR (1) | BR112016013157A2 (enExample) |
| CA (1) | CA2933405A1 (enExample) |
| MX (1) | MX2016007407A (enExample) |
| SG (1) | SG10201805039UA (enExample) |
| WO (1) | WO2015086686A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726889B (zh) | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| WO2017075505A2 (en) * | 2015-10-28 | 2017-05-04 | Tufts University | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
| JP2019525732A (ja) | 2016-06-09 | 2019-09-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | プロテアーゼ耐性一脂質付加ペプチド |
| CA3073806A1 (en) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| DK3774862T3 (da) | 2018-04-05 | 2022-09-05 | Sun Pharmaceutical Ind Ltd | Nye GLP-1-analoger |
| AU2021250319A1 (en) * | 2020-03-31 | 2022-12-01 | Antaros Medical Ab | Selective GIP receptor agonists comprising a chelating moiety for imaging and therapy purposes |
| KR20230120134A (ko) * | 2020-12-16 | 2023-08-16 | 메디뮨 리미티드 | 폴리펩티드 및 이의 용도 |
| TW202346323A (zh) * | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1495198A (zh) * | 1998-12-07 | 2004-05-12 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 胰高血糖素样肽-1的类似物 |
| WO2007090496A1 (en) * | 2006-02-08 | 2007-08-16 | Lonza Ag | Synthesis of glucagon-like peptide |
| WO2007139589A1 (en) * | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| WO2008023050A1 (en) * | 2006-08-25 | 2008-02-28 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| WO2009125424A2 (en) * | 2007-12-11 | 2009-10-15 | Cadila Healthcare Limited | Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities |
| ATE487732T1 (de) * | 2008-04-18 | 2010-11-15 | Hoffmann La Roche | Alpha-n-methylierung von aminosäuren |
| US20120264685A1 (en) * | 2009-10-22 | 2012-10-18 | Rajesh Bahekar | Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist |
| US20130143800A1 (en) * | 2011-11-07 | 2013-06-06 | Research Development Foundation | Combination therapies to treat diabetes |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| WO2014088631A1 (en) * | 2012-12-06 | 2014-06-12 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
-
2014
- 2014-12-10 AU AU2014363547A patent/AU2014363547A1/en not_active Abandoned
- 2014-12-10 CN CN201480067307.1A patent/CN105849123A/zh active Pending
- 2014-12-10 US US15/103,607 patent/US20160318987A1/en not_active Abandoned
- 2014-12-10 WO PCT/EP2014/077240 patent/WO2015086686A2/en not_active Ceased
- 2014-12-10 EP EP14809857.7A patent/EP3080153A2/en not_active Withdrawn
- 2014-12-10 SG SG10201805039UA patent/SG10201805039UA/en unknown
- 2014-12-10 JP JP2016538037A patent/JP2017502003A/ja active Pending
- 2014-12-10 KR KR1020167018887A patent/KR20160098406A/ko not_active Withdrawn
- 2014-12-10 CA CA2933405A patent/CA2933405A1/en not_active Abandoned
- 2014-12-10 BR BR112016013157A patent/BR112016013157A2/pt not_active Application Discontinuation
- 2014-12-10 EP EP18182275.0A patent/EP3415526A1/en not_active Withdrawn
- 2014-12-10 MX MX2016007407A patent/MX2016007407A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015086686A2 (en) | 2015-06-18 |
| EP3415526A1 (en) | 2018-12-19 |
| WO2015086686A3 (en) | 2015-10-29 |
| CN105849123A (zh) | 2016-08-10 |
| EP3080153A2 (en) | 2016-10-19 |
| CA2933405A1 (en) | 2015-06-18 |
| AU2014363547A1 (en) | 2016-06-30 |
| SG10201805039UA (en) | 2018-07-30 |
| KR20160098406A (ko) | 2016-08-18 |
| BR112016013157A2 (pt) | 2017-09-26 |
| US20160318987A1 (en) | 2016-11-03 |
| JP2017502003A (ja) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125302T1 (el) | Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας | |
| MX2016007407A (es) | Peptidos resistentes a proteasa. | |
| EA202090919A1 (ru) | Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a | |
| MX341324B (es) | Polipeptidos. | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. | |
| MX2012001194A (es) | Peptidos tau antigenicos y usos de los mismos. | |
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| UA109949C2 (uk) | Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| EA201390156A1 (ru) | ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ | |
| PH12017502259A1 (en) | Protease-resistant lipidated glp-1 analogs | |
| GB201118201D0 (en) | Novel peptides | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| EA201692439A1 (ru) | Пролин-специфичная эндопротеаза и ее применение | |
| NZ596501A (en) | Casb7439 constructs | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| EP3925968A3 (en) | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |